Thomas Walden, MD
Radiation Oncology · Lumberton, NCNPI 1447214028
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.9% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $562 and has fallen 88.4% since, to $65 in 2024.
Across 104 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$234
- Gilead$166
- Amgen$164
- Merck$127
- Novartis$122
- Exelixis Inc.$121
- plus $887 from 27 others
What the payments were for
- Food & beverage$1,67392%
- Education$1488%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 9 | $234 |
| Gilead | 11 | $166 |
| Amgen | 11 | $164 |
| Merck | 7 | $127 |
| Novartis | 6 | $122 |
| Exelixis Inc. | 8 | $121 |
| Daiichi Sankyo Inc. | 5 | $98 |
| Sanofi | 4 | $64 |
| Myovant Sciences Inc. | 3 | $61 |
| Bristol Myers Squibb | 3 | $59 |
| Lilly USA, LLC | 4 | $57 |
| AstraZeneca(2 entities) | 3 | $53 |
| Boston Scientific | 1 | $48 |
| Seagen Inc. | 3 | $41 |
| Genentech USA, Inc. | 4 | $39 |
| Incyte Corporation | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 3 | $38 |
| Varian Medical Systems, Inc. | 1 | $30 |
| Boehringer Ingelheim | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| EUSA Pharma (US) LLC | 1 | $23 |
| Pfizer | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Beigene USA, Inc. | 1 | $19 |
| G1 Therapeutics, Inc. | 1 | $17 |
| Dova Pharmaceuticals | 1 | $15 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $15 |
| Rigel Pharmaceuticals, Inc. | 1 | $14 |
| Mirati Therapeutics, Inc. | 1 | $14 |
| Bayer | 1 | $12 |
| Tersera Therapeutics LLC | 1 | $12 |
| Advanced Accelerator Applications | 1 | $12 |
| Sirtex Medical Inc | 1 | $7 |
How this compares
$1,821 in reported general payments places this provider in the 75th percentile of 199 radiation oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pilocarpine Hcl | 22 | $2,022 |
| Memantine Hcl | 11 | $215 |
| Tamsulosin Hcl | 17 | $187 |
| Lorazepam | 17 | $24 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Lumberton
- Andrew WangChapel Hill$118K
- Volker StieberWinston Salem$99K
- Lewis SulmanDurham$54K
- Michael PapagikosWilmington$51K
- William LeeDurham$37K
- Matthew ManningGreensboro$33K
- Michael ChanWinston Salem$32K
- John KirkpatrickDurham$29K
- John HeinzerlingCharlotte$29K
- Brian CzitoDurham$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.